To clarify, 2QFY2025 = 4Q2024 = Oct ~ Dec 2024 = quarter ending December 2024 . (For the newcomers).
"NYR-BI03 is currently undergoing GLP safety and tolerability studies ahead of a first-in-human Phase I clinical trial expected to commence in the quarter ending December 2024.
Thus far, six out of nine GLP studies have been completed.
Subject to satisfactory completion of this Phase I trial, NYR-BI03 has the potential to progress directly to Phase II trials to assess its efficacy in the following" '3' treatment Markets:
1. Stroke
2. Traumatic brain injury, and now
3. Myocardial ischemia-reperfusion injury.
Regarding 3. above, (todays announcement content), currently, "it is a great challenge in the therapy of cardiovascular disease and a common clinical complication".
Current treatment includes Captopril or Capoten, an FDA-approved ACE inhibitor commonly administered following ischhttps://www.sciencedirect.com/science/article/pii/S001948321630236Xemic events and used in this study as a positive control. Captopril is owned by Global BioPharma co. Bristol-Myers Squibb...
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)